Technical Considerations in the choice and use of ctDNA for Large B-cell lymphoma (LBCL).

Authors

Joanna A Krupka, Christiane Pott, Daniel J Hodson

Published in

Blood. Sep 03, 2026. Epub Sep 03, 2026.

Abstract

Diffuse Large B-cell lymphoma is an aggressive lymphoma in which management is constrained by incomplete molecular characterization and the absence of sensitive markers of treatment response. Cell-free DNA offers a noninvasive approach for tumor genotyping and minimal residual disease monitoring. Nevertheless, technical challenges persist, including low cfDNA abundance and the discrimination of low allele fraction variants from background noise. Tumor-informed assays tracking multiple genetic markers substantially improve sensitivity of disease monitoring. Standardization and prospective validation will facilitate routine clinical implementation.

PMID:
42691013
Bibliographic data and abstract were imported from PubMed on 04 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.